SCHEMBL2221075

SCHEMBL2221075

Nc1cncc(N2CCOCC2)c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
GAA P10253 4/20 0.46
THRB P10828 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 2/20 0.46
POLB P06746 2/20 0.46
KMT2A Q03164 2/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LGMN Q99538 2/20 0.46
KDM4E B2RXH2 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NCF1 P14598 1/20 0.40
CTSK P43235 2/20 0.39
SMPD3 Q9NY59 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15301290 0.82 KEAP1 (0.48) MAPTGAATHRBALDH1A1MEN1
SCHEMBL2222784 0.78 ADRA2C (0.50) MAPTGAAALDH1A1POLBKMT2A
SCHEMBL23498989 0.76 LGMN (0.53) MAPTGAATHRBALDH1A1MEN1
SCHEMBL30309939 0.76 MAPT (0.55) MAPTGAATHRBALDH1A1MEN1
SCHEMBL14881721 0.76 MAPT (0.55) MAPTGAATHRBALDH1A1MEN1
SCHEMBL2222744 0.76 MAPT (0.53) MAPTGAAALDH1A1MEN1POLB
SCHEMBL16040071 0.73 MAPT (0.49) MAPTGAATHRBALDH1A1MEN1
SCHEMBL31248708 0.72 LGMN (0.51) MAPTGAATHRBALDH1A1MEN1
SCHEMBL904453 0.72 LGMN (0.51) MAPTGAATHRBALDH1A1MEN1
SCHEMBL11907690 0.71 MAPT (0.50) MAPTGAATHRBALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116878-A1 INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF BIOSPLICE THERAPEUTICS INC (US) 2026-04-30 US disclosed
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS KUDA THERAPEUTICS INC (US) 2025-11-13 US disclosed
EP-4531838-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS Kuda Therapeutics, Inc. (US) 2025-04-09 EP disclosed
US-20240116927-A1 INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2024-04-11 US disclosed
WO-2023234970-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS KUDA Therapeutics, Inc. (US) 2023-12-07 WO disclosed
US-11697649-B2 Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-07-11 US disclosed
US-11697649-B2 Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-07-11 US disclosed
US-11697649-B2 Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-07-11 US disclosed
US-20230013144-A1 INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF TENARX, INC. 2023-01-19 US disclosed
US-20230013144-A1 INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF TENARX, INC. 2023-01-19 US disclosed
US-20130225576-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2013-08-29 US disclosed
US-8450340-B2 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2013-05-28 US disclosed
US-8450340-B2 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2013-05-28 US disclosed
US-8450340-B2 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2013-05-28 US disclosed
EP-2515655-A1 1H-PYRAZOLO[3,4-BETA]PYRIDINES AND THERAPEUTIC USES THEREOF Samumed, LLC (US) 2012-10-31 EP disclosed
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 US disclosed
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 US disclosed
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 US disclosed
WO-2011084486-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-07-14 WO disclosed
WO-2011084486-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK MAPT 2756/4885GAA 2943/4885THRB 1071/4885
US-20130225576-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK MAPT 2756/4885GAA 2943/4885THRB 1071/4885
US-11697649-B2 Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof WNT1, WNT3, WNT3A MAPT 154/4885GAA 2480/4885THRB 2708/4885
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS HIF1AN, HIF1A, EGLN2 MAPT 4577/4885GAA 3085/4885THRB 1463/4885
US-20230013144-A1 INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MAPT 154/4885GAA 2480/4885THRB 2708/4885
US-20240116927-A1 INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MAPT 154/4885GAA 2480/4885THRB 2708/4885
US-20260116878-A1 INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MAPT 1206/4885GAA 4332/4885THRB 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.